'Ocean Biomed Breakthrough Findings in EGFR-Mutant Lung Cancer, Plans FDA Alignment'

 Poised to Enter Booming Bispecific Antibody Market Amid Growing Pharma Interest

Ocean Biomedical (NASDAQ: OCEA) today announced newly published research findings demonstrating the ability of its proprietary cancer immunotherapy candidates to favorably interact with tyrosine kinase inhibitors (TKI), such as osimertinib that are used to treat non-small cell lung cancer (NSCLC). Specifically, they demonstrate that Ocean’s immunotherapy candidates provide synergy with the TKI therapies (gefitinib and osimertinib) to suppress tumor growth and progression. In addition, the paper’s findings demonstrate that its proprietary cancer immunotherapy candidates have a remarkable ability to restore treatment sensitivity following development of osimertinib resistance. This breakthrough offers a potential paradigm shift in the treatment of Epidermal Growth Factor Receptor (EGFR)-mutant NSCLC and could expand treatment options for patients whose tumors are no longer responding to tyrosine kinase inhibitors.

Ocean Biomedical is initiating preclinical studies to advance its immunotherapy program and will engage with the FDA this year to align on a regulatory pathway for first-in-human trials.

https://www.globenewswire.com/news-release/2025/02/10/3023373/0/en/Ocean-Biomedical-Announces-Breakthrough-Findings-in-EGFR-Mutant-Lung-Cancer-and-Plans-for-FDA-Alignment-on-Next-Stage-Development.html